Solid Biosciences

Solid Biosciences, Inc. engages in the development of treatments for patients with Duchenne muscular dystrophy (DMD). It develops gene therapies, disease modifying therapies, and assistive devices for the cure of DMD. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Bennett Arnold, Annie Ganot, and Gilad David Hayeem in March 2013 and is headquartered in Charlestown, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Solid Biosciences, Inc. is a life science company, which engages in the development of treatments for patients with Duchenne muscular dystrophy. It also focuses on developing treatments for neuromuscular and cardiac diseases. The company was founded by Ilan Ganot, Andrey J. Zarur, Matthew Bennett Arnold, Annie Ganot, and Gilad David Hayeem in March 2013 and is headquartered in Charlestown, MA.

CAMBRIDGE, Mass., March 23, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc., (Nasdaq: SLDB) a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the closing of its previously announced underwritten public offering of 25,000,000 shares of its common stock at a public offering price of $5.75 per share, including 3,260,869 shares sold pursuant to the full exercise of the underwriters' option to purchase additional shares. Gross proceeds from the sale of the shares, before deducting underwriting discounts and commissions and offering expenses, were approximately $143.8 million.

Solid Biosciences Announces Closing of Public Offering and Full Exercise of Over-Allotment Option

CAMBRIDGE, Mass., March 18, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc., (Nasdaq: SLDB) a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that it has priced an underwritten public offering of 21,739,131 shares of its common stock at a public offering price of $5.75 per share, for total gross proceeds of $125.0 million, before deducting underwriting discounts and commissions and offering expenses. In addition, Solid has granted the underwriters a 30-day option to purchase up to an additional 3,260,869 shares of its common stock on the same terms and conditions. All of the shares in the offering are being sold by Solid. The offering is expected to close on March 23, 2021, subject to customary closing conditions.

Solid Biosciences Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass., March 17, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc., (Nasdaq: SLDB) a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that it has commenced an underwritten public offering of $85 million of shares of its common stock. All of the shares are being offered by Solid. In addition, Solid expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock sold in the public offering on the same terms and conditions.

Solid Biosciences Announces Proposed Public Offering of Common Stock

Solid Biosciences' (SLDB) lead gene therapy candidate achieves positive improvements in DMD patients. However, it fails to cheer investors.

Solid Biosciences (SLDB) Announces DMD Study Data, Stock Down

Investors appear to be skeptical about the biotech's latest clinical update.

Why Solid Biosciences Stock Is Crashing Today

Solid Biosciences Inc (NASDAQ: SLDB) reported interim functional, biomarker data, and patient-reported outcome measures from its ongoing IGNITE Phase 1/2 trial of its lead gene therapy candidate, SGT-001 in Duchenne muscular dystrophy (DMD). While IGNITE-DMD was designed to assess the microdystrophin protein expression and distribution, the company instead chose to highlight the functional and patient-reported outcomes at the 12-month mark.

Solid Bio's DMD Gene Therapy Shows Promising Early Data, No New Safety Concerns, But Fails To Cheer Investors

- Interim data from six patients provide evidence of a potential benefit of SGT-001 in functional endpoints of North Star Ambulatory Assessments (NSAA), 6-minute walk test (6MWT), pulmonary function tests (PFTs), and clinically validated patient reported outcome measures (PROMs) -

Solid Biosciences Reports Efficacy and Safety Data from the Ongoing IGNITE DMD Clinical Trial and Resumption of Patient Dosing in the 2E14 vg/kg Cohort

CAMBRIDGE, Mass., March 04, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced the grant of an inducement award to its newly appointed Chief Legal Officer, Erin Brennan. The grant was approved by a majority of the independent directors of the Company on February 25, 2021 as an inducement material to Ms. Brennan entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).

Solid Biosciences Reports Inducement Grant to New Chief Legal Officer

-Adding senior level experience to help advance programs for Duchenne muscular dystrophy-

Solid Biosciences Announces Appointments to Management Team and Board of Directors

- IGNITE DMD Principal Investigator, Dr. Barry Byrne, to present efficacy and safety data from the ongoing IGNITE DMD trial on Thursday, March 18-

Efficacy and Safety Data from Solid Biosciences' Ongoing IGNITE DMD Phase I/II Clinical Trial to be Presented at the 2021 MDA Clinical & Scientific Conference

CAMBRIDGE, Mass., Feb. 17, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Joel Schneider, PhD, Chief Technology Officer, and Cathryn Clary, MD, MBA, Acting Chief Medical Officer, will participate at the following two upcoming investor conferences:

Solid Biosciences to Present at Upcoming Investor Conferences

Why Solid Biosciences Stock Is Sinking Today

CAMBRIDGE, Mass., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Ilan Ganot, Chief Executive Officer, President and Co-Founder, will present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021 at 8:20 am ET. Following the prepared remarks, several members of the leadership team will be available for Q&A.

Solid Biosciences to Present at 39th Annual J.P. Morgan Healthcare Conference

vTv Therapeutics

SELLAS Life Sciences Group

Tv Therapeutics (NASDAQ: VTVT) shares were trading higher on Friday after the company said its Phase 2 Simplici-T1 study of TTP399 achieved the primary objective of a statistically significant reduction in HbA1c. Tv Therapeutics Inc operates in the United States health care sector.

Why 3 Health Care Stocks Are Moving: Tv Therapeutics, Solid Biosciences, Sellas Life Sciences

CAMBRIDGE, Mass., Dec. 11, 2020 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that it has entered into a securities purchase agreement with a select group of institutional investors and accredited investors for a $90 million private placement, which is expected to close on or about December 15, 2020, subject to the satisfaction of customary closing conditions.

Solid Biosciences Announces $90 Million Private Placement

Investors need to pay close attention to Solid Biosciences (SLDB) stock based on the movements in the options market lately.

Are Options Traders Betting on a Big Move in Solid Biosciences (SLDB) Stock?

SLDB is recovering from clinical holds placed on lead drug candidate SGT-001 for DMD. They entered a new deal with Ultragenyx, and have cash for the next year.

Solid Biosciences: Does Not Look Like A Solid Investment Given Its Unsatisfactory Trial Data

Solid Biosciences' (SLDB) CEO Ilan Ganot on Q3 2020 Results - Earnings Call Transcript

Solid Biosciences??? (SLDB) reports wider than expected loss in the third quarter of 2020.

Solid Biosciences (SLDB) Reports Wider-Than Expected Q3 Loss

–IGNITE DMD clinical trial expected to resume dosing in the first quarter of 2021 –

Solid Biosciences Reports Third Quarter 2020 Financial Results and Provides Business Update

CAMBRIDGE, Mass., Nov. 03, 2020 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that it will release third quarter 2020 financial results before the market opens on Thursday, November 5, 2020. Management will host a conference call on the same date beginning at 8:30 a.m. ET to discuss the Company's financial results and recent business developments.

Solid Biosciences to Host Third Quarter 2020 Financial Results and Business Update Call on November 5, 2020

Solid Biosciences (SLDB) will provide updates on its lead pipeline candidate,SGT-001, along with others when it releases third-quarter 2020 results.

Solid Biosciences (SLDB) to PostQ3 Earnings: What's in Store?

Do Options Traders Know Something About Solid Biosciences (SLDB) Stock We Don't?

CAMBRIDGE, Mass., Oct. 02, 2020 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy (Duchenne), today announced that Jennifer Ziolkowski, Chief Financial Officer, Joel Schneider, Chief Technology Officer and Cathryn Clary, Interim Chief Medical Officer, will participate in a virtual fireside chat at the Chardan 4th Annual Genetic Medicines Conference on Tuesday, October 6, 2020 at 4:45 pm ET.

Solid Biosciences to Participate in Virtual Fireside Chat at the Chardan 4th Annual Genetic Medicines Conference

Solid Biosciences Inc. (NASDAQ: SLDB) shares more than doubled on Thursday after the company announced a key update from the U.S. Food and Drug Administration (FDA). Essentially, the agency has decided to lift a clinical hold placed on the firm in July 2020.

News for Solid Biosciences Stock (SLDB)